Therapeutic Modalities in Neurodegeneration

Migration, Crosslink

📖

Therapeutic Modalities in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-therapeutic-modalities

📖 Wiki Page

therapeutic2951 wordssynced 2026-04-02

Therapeutic Modalities in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Therapeutic Modalities in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Modality</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Antibody Therapies</td>
<td>Bind and clear pathological proteins</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Deliver genetic material to modify cellular function</td>
</tr>
<tr>
<td class="label">ASOs</td>
<td>Modulate RNA splicing/protein production</td>
</tr>
<tr>
<td class="label">Small Molecules</td>
<td>Inhibit or modulate protein function</td>
</tr>
<tr>
<td class="label">Cell Therapy</td>
<td>Replace lost [neurons](/entities/neurons)/support cells</td>
</tr>
<tr>
<td class="label">Targeted Protein Degradation</td>
<td>Eliminate specific proteins via proteasome</td>
</tr>
</table>

...

Therapeutic Modalities in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Therapeutic Modalities in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Modality</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Antibody Therapies</td>
<td>Bind and clear pathological proteins</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>Deliver genetic material to modify cellular function</td>
</tr>
<tr>
<td class="label">ASOs</td>
<td>Modulate RNA splicing/protein production</td>
</tr>
<tr>
<td class="label">Small Molecules</td>
<td>Inhibit or modulate protein function</td>
</tr>
<tr>
<td class="label">Cell Therapy</td>
<td>Replace lost [neurons](/entities/neurons)/support cells</td>
</tr>
<tr>
<td class="label">Targeted Protein Degradation</td>
<td>Eliminate specific proteins via proteasome</td>
</tr>
</table>

Neurodegenerative diseases like [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) represent some of the greatest challenges in modern medicine. While the underlying pathological mechanisms involve complex interactions between genetic susceptibility, protein aggregation, neuroinflammation, and cellular dysfunction, developing disease-modifying therapies has proven remarkably difficult. The failure of numerous high-profile clinical trials, particularly in Alzheimer's disease, has led to a fundamental rethinking of therapeutic strategies and an appreciation that multiple complementary approaches may be necessary[@long2019].

The therapeutic landscape for neurodegenerative diseases has expanded dramatically in recent years, moving beyond symptomatic treatments toward disease-modifying approaches that target the core pathological processes. This page provides a comprehensive comparison of the major therapeutic modalities currently in development or clinical use, including antibody therapies, gene therapy, antisense oligonucleotides, small molecule drugs, cell therapy, and targeted protein degradation. Each modality offers distinct advantages and limitations, and the field is increasingly exploring combination approaches that may prove more effective than any single intervention[@karch2015].

Understanding the strengths and weaknesses of each therapeutic approach is essential for appreciating the current state of drug development and the challenges that remain. The choice of therapeutic modality depends on multiple factors, including the specific molecular target, the accessibility of the central nervous system, the nature of the disease pathology, and the stage of clinical development.

Pathway Diagram

Mermaid diagram (expand to render)

Comparison of Therapeutic Modalities

Antibody Therapies

Mechanism of Action

Antibody therapies leverage the immune system to target and clear pathological proteins that accumulate in neurodegenerative diseases. Monoclonal antibodies are designed to bind specifically to target proteins such as [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), or [alpha-synuclein](/proteins/alpha-synuclein), marking them for clearance by the immune system[@panza2019]. This approach has shown significant promise in Alzheimer's disease, with two antibodies—lecanemab and donanemab—receiving regulatory approval in 2023 and 2024 respectively.

The therapeutic antibody approaches can be categorized by their target:

Anti-amyloid antibodies: Target various forms of amyloid-beta plaques, including soluble oligomers and fibrillar deposits
Anti-tau antibodies: Target phosphorylated tau tangles and their oligomeric precursors
Anti-alpha-synuclein antibodies: Target Lewy body pathology in Parkinson's disease and related disorders

Clinical Status

The field of antibody therapeutics for neurodegeneration has reached a critical milestone with the approval of lecanemab (Leqembi) and dononemab (Kisunla) for early Alzheimer's disease. These approvals represent the first disease-modifying therapies for Alzheimer's and validate the amyloid hypothesis, though they come with important limitations and safety concerns[@van2023].

Key programs in clinical development include:

Prasinezumab (Roche/Genentech): Anti-alpha-synuclein antibody for Parkinson's disease, showing slowed motor progression in some patients[@pagano2022]
Semorinemab (Genentech): Anti-tau antibody that failed in the LAURIET trial for mild cognitive impairment
Tilavonemab (AbbVie): Anti-tau antibody that failed in Phase 2 for progressive supranuclear palsy

Key Companies

Major pharmaceutical companies advancing antibody therapies include:

Eisai/Biogen: Lecanemab (approved), JNJ-63742057 (next-generation anti-amyloid)
Eli Lilly: Donanemab (approved), Remternetug (皮下注射 anti-amyloid)
Roche/Genentech: Prasinezumab, Semorinemab
AbbVie: Tilavonemab, ABBV-916 (anti-tau)
Prothelia: Anti-tau antibody programs

Advantages

Antibody therapies offer several significant advantages:

High specificity: Engineered to bind with exceptional affinity to specific protein epitopes
Proven efficacy: Demonstrated disease modification in Alzheimer's disease
Well-characterized safety profiles: Extensive clinical trial experience
Scalable manufacturing: Established biopharmaceutical production methods

Limitations

Despite their promise, antibody therapies face important challenges:

High cost: Annual treatment costs exceeding $30,000
Brain delivery barriers: Only small fractions reach the CNS after peripheral administration
Amyloid-related imaging abnormalities (ARIA): Brain edema and microhemorrhages require monitoring
Limited efficacy: Benefits are modest despite high costs
Late-stage intervention: Treatment likely less effective in advanced disease

Gene Therapy

Mechanism of Action

Gene therapy involves delivering genetic material into target cells to either:

Replace deficient genes (e.g., [GBA](/genes/gba) mutations in Parkinson's disease)
Overexpress protective proteins (e.g., neurotrophic factors)
Knockdown disease-causing genes using RNA interference
Modulate gene expression to enhance cellular resilience[@hudry2022]

The most common delivery vehicles are adeno-associated viruses (AAV), which can transduce post-mitotic neurons, persist for extended periods without integrating into the host genome, and have relatively low immunogenicity.

Clinical Status

Gene therapy for neurodegenerative diseases remains largely in early-stage development, with several programs in Phase 1 and Phase 2 trials. The field has been advanced by successes in other neurological conditions, particularly spinal muscular atrophy with onasemnogene abeparvovec (Zolgensma) and various AAV programs for rare metabolic disorders[@mendell2017].

Key programs in development include:

AAV-GRN (Yumanity/Biogen): For frontotemporal dementia with GRN mutations
AAV-GAA (Spark Therapeutics): For neuronopathic Gaucher disease
VY-AADC (Voyager Therapeutics): Gene therapy delivering AADC enzyme for Parkinson's disease
AAV-hGBA1 (Prevail Therapeutics/Lilly): For Parkinson's disease with GBA mutations

Key Companies

Companies advancing gene therapy for neurodegeneration include:

Voyager Therapeutics: AAV-based programs for Parkinson's and Alzheimer's
Biogen/Yumanity: GRN and other genetic targets
Spark Therapeutics/Roche: Lysosomal storage disease programs
Prevail Therapeutics/Lilly: GBA-associated Parkinson's disease
Neurocrine Biosciences: Gene therapy partnerships

Advantages

Gene therapy offers unique advantages:

Potential for durable effects: Single administration may provide years of benefit
Target genetic root causes: Particularly valuable for monogenic forms of disease
Precise molecular targeting: Can deliver any gene sequence
Potential for disease modification: Address underlying pathophysiology rather than symptoms

Limitations

Significant challenges remain:

Delivery to the CNS: Requires invasive neurosurgical delivery or sophisticated vector engineering
Immune responses: Pre-existing antibodies to AAV vectors limit repeat dosing
Cargo capacity limits: AAV can only deliver relatively small genetic payloads
Safety concerns: Integration events, off-target effects, and insertional mutagenesis
Manufacturing complexity: Scalable, cost-effective production remains challenging
Regulatory hurdles: Long-term follow-up requirements increase development costs and timelines

Antisense Oligonucleotides (ASOs)

Mechanism of Action

Antisense oligonucleotides are short, synthetic single-stranded DNA sequences that bind to specific messenger RNA (mRNA) targets via Watson-Crick base pairing. This binding either:

Directs RNase H degradation: ASO-RNA hybrid triggers intracellular RNase H to cleave the RNA
Modulates splicing: ASOs can mask or reveal splice sites to alter protein isoforms[@rinaldi2018]

ASOs can reduce production of disease-causing proteins, restore normal splicing patterns, or increase expression of protective protein variants. The technology has proven particularly valuable for neurological diseases where reducing a toxic protein can provide clinical benefit.

Clinical Status

ASO therapy has achieved clinical success in several neurodegenerative diseases, with tofersen (Qalsody) receiving FDA approval in 2023 for SOD1-associated amyotrophic lateral sclerosis[@miller2023]. This approval represents a major milestone for the modality and validates the approach for targeting neurodegenerative proteins.

Key programs in development include:

IONIS-MAPTRx (Ionis/Biogen): Anti-sense drug reducing [tau protein](/proteins/tau) production, showing biomarker benefits in Phase 1/2[@ionis2023]
IONIS-HTTRx (Ionis/Roche): For Huntington's disease, demonstrating dose-dependent reduction of mutant [huntingtin protein](/proteins/huntingtin)
ASOs for [C9orf72](/entities/c9orf72): Programs targeting the most common genetic cause of ALS and frontotemporal dementia
ASOs for [TDP-43](/mechanisms/tdp-43-proteinopathy): Emerging programs addressing TDP-43 proteinopathy

Key Companies

The ASO field is dominated by a few key players:

Ionis Pharmaceuticals: Pioneering ASO technology with most advanced programs
Biogen: Major partner and commercializer of ASO therapies
Roche: Partnership with Ionis for Huntington's and other programs
Alnylam: Expanding beyond siRNA into ASO space
Wave Life Sciences: Stereopure ASO programs for neurological diseases

Advantages

ASO therapies offer distinctive benefits:

Precise target engagement: Directly modify RNA to control protein production
CNS delivery: Systemically administered ASOs reach the brain and spinal cord
Predictable pharmacology: Dose-dependent, reversible effects
Modular design: ASOs can be designed against any target RNA sequence
Proven regulatory pathway: Multiple approvals in neurological diseases

Limitations

Challenges that remain include:

Off-target effects: Sequences with partial complementarity may unintendedly affect other RNAs
Repeat dosing: Most ASOs require periodic administration (monthly to quarterly)
Delivery to specific cell types: Distribution is largely to glial cells rather than neurons
Delivery to specific brain regions: Spinal cord and cortical regions are well-reached, but deep brain structures are more challenging
Safety monitoring: Liver function and platelet counts require regular monitoring
Cost: Similar to antibodies, annual costs exceed $100,000 for many programs

Small Molecule Drugs

Mechanism of Action

Small molecule drugs are low-molecular-weight compounds (typically <500 Da) that can penetrate the [blood-brain barrier](/entities/blood-brain-barrier) and modulate the activity of specific protein targets. In neurodegeneration, small molecules target various aspects of disease pathogenesis[@cummings2023]:

Enzyme inhibitors: [BACE1](/entities/bace1), [gamma-secretase](/entities/gamma-secretase), LRRK2 kinase, MAO-B
Receptor modulators: [NMDA receptor](/entities/nmda-receptor) antagonists, [GLP-1 receptor](/entities/glp1-receptor) agonists
Protein aggregation inhibitors: Modulators of amyloid-beta, tau, alpha-synuclein aggregation
Neuroprotective compounds: Mitochondrial stabilizers, antioxidants, anti-inflammatory agents

Clinical Status

Small molecules remain the most common therapeutic approach and include the only approved disease-modifying treatments for Parkinson's disease (MAO-B inhibitors provide modest symptomatic benefit). Recent developments include:

Approved treatments:

Levodopa/carbidopa: Gold standard for Parkinson's symptom management
MAO-B inhibitors (selegiline, rasagiline, safinamide): Mild disease-modifying effects
[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) ([donepezil](/entities/donepezil), [rivastigmine](/entities/rivastigmine), galantamine): Symptomatic benefit in Alzheimer's
Edaravone: FDA-approved for ALS, shows modest benefit

In development:

BACE inhibitors (verubecestat, umibecestat): Failed due to cognitive worsening despite reducing amyloid
LRRK2 inhibitors (DNL151, BIIB122): Phase 2/3 in Parkinson's disease[@jennings2023]
KMO inhibitors: Targeting neuroinflammation in ALS and Alzheimer's
GLP-1 receptor agonists (exenatide, liraglutide): Showing promise in Parkinson's disease[@athauda2017]

Key Companies

Major pharmaceutical companies with small molecule programs include:

AbbVie: LRRK2 inhibitor program, Parkinson's disease
Biogen: BACE inhibitors (failed), GLP-1 programs
UCB: Parkinson's disease programs
Denali Therapeutics: LRRK2 and other programs
Alzheimer's Drug Discovery Foundation: Funded numerous small molecule programs
Cerevel Therapeutics: Multiple neuroscience programs

Advantages

Small molecules offer several practical advantages:

Oral bioavailability: Patient-friendly administration
Blood-brain barrier penetration: Well-established CNS distribution
Manufacturing scalability: Cost-effective large-scale production
Established regulatory pathways: Extensive precedent for small molecule drugs
Combinability: Multiple small molecules can be used together

Limitations

Key limitations include:

Lower specificity: Often hit multiple targets, leading to side effects
Toxicity: Long-term safety concerns with chronic dosing
Limited efficacy: Most provide symptomatic benefit rather than disease modification
Target accessibility: Some disease-relevant proteins are not druggable with small molecules
Failure rate: BACE inhibitor failures illustrate the high attrition in this space

Cell Therapy

Mechanism of Action

Cell therapy involves transplanting living cells into patients to replace lost neurons, provide trophic support, or modulate the immune system. The field has evolved from early transplant approaches using fetal tissue to contemporary strategies using stem cell-derived populations[@barker2023]:

Neuronal replacement: Transplanting neurons or neuronal progenitors to replace lost cells
Glial cell replacement: Providing healthy [microglia](/cell-types/microglia-neuroinflammation) or [astrocytes](/entities/astrocytes) to support neuronal function
Trophic factor delivery: Cells engineered to secrete neuroprotective factors
Immunomodulation: Regulatory immune cells to dampen neuroinflammation

Clinical Status

Cell therapy for neurodegeneration is still in early-stage clinical development, with most programs in Phase 1 or Phase 2. The field has been advanced by successes in other areas, particularly hematopoietic stem cell transplantation and CAR-T cell therapy.

Key programs include:

iPSC-derived dopaminergic neurons (Kyowa Hakko Kirin/iPS Japan): Phase 1/2 in Parkinson's disease
Mircoglial replacement (Aspen Neuroscience): Preclinical/Phase 1 for Alzheimer's disease
Neural progenitor cells (Neuralstem): Phase 2 in ALS
Encapsulated cell biodelivery (Nzymebios): Delivering trophic factors

Key Companies

Companies advancing cell therapy include:

Aspen Neuroscience: iPSC-derived therapies for Parkinson's and Alzheimer's
BlueRock Therapeutics/Bayer: iPSC-derived neuronal therapies
Sana Biotechnology: Cell therapy for CNS disorders
Lineage Cell Therapeutics: Retinal and neural cell programs
Nzymebios: Encapsulated cell biodelivery

Advantages

Cell therapy offers unique mechanisms:

Cellular replacement: Potential to replace lost neurons and restore function
Trophic support: Continuous delivery of protective factors
Immune modulation: Can address neuroinflammation
Disease modeling: Patient-derived iPSCs enable disease modeling and drug screening
Personalized medicine: Autologous iPSC-derived cells may avoid immune rejection

Limitations

Significant scientific and practical challenges:

Tumor risk: Undifferentiated stem cells may form teratomas
Immune rejection: Allogeneic cells face immune attack
Delivery challenges: Safe and precise transplantation to appropriate brain regions
Survival and integration: Transplanted cells must survive, integrate, and function in the hostile disease environment
Manufacturing complexity: Autologous iPSC approaches are expensive and time-consuming
Limited efficacy data: Early-stage trials have yet to demonstrate clear clinical benefit

Targeted Protein Degradation

Mechanism of Action

Targeted protein degradation is an emerging therapeutic modality that eliminates specific proteins by hijacking the cell's natural degradation machinery. The two main approaches are[@bks2022]:

PROTACs (Proteolysis-Targeting Chimeras): Bifunctional molecules with one domain binding the target protein and another binding an E3 ubiquitin ligase. This brings the target into proximity for ubiquitination and subsequent degradation by the proteasome.

Molecular glues: Small molecules that stabilize interactions between a target protein and an E3 ligase, leading to degradation. These are typically monovalent and can induce degradation without the bivalent architecture of PROTACs.

Clinical Status

Targeted protein degradation is the newest modality in the neurodegeneration space, with most programs still in preclinical development. However, the technology has achieved multiple approvals in oncology (lenalidomide, pomalidomide, ARV-110, ARV-471), validating the platform[@mullard2024].

Key programs in development include:

PROTACs for tau: Several programs targeting tau aggregation
Molecular glues for alpha-synuclein: Preclinical programs
PROTACs for TDP-43: Emerging programs
Glue degraders for LRRK2: Preclinical

Key Companies

Companies advancing targeted protein degradation include:

Arvinas: PROTAC platform, multiple CNS programs
BMS/Celgene: Molecular glue programs
Nurix Therapeutics: Targeted protein degradation
BioTheryX: PROTAC programs
Accutar Biotechnology: AI-enabled degrader discovery
Minority/unicorn startups: Numerous early-stage companies

Advantages

This novel modality offers unique advantages:

Substoichiometric activity: One degraser molecule can eliminate multiple target molecules
Novel mechanisms: Can target proteins considered "undruggable" by traditional approaches
Potential for reversible effects: Withdrawal allows protein recovery
Overcoming resistance: Different mechanism may bypass resistance to inhibitors

Limitations

Significant challenges remain:

CNS delivery: Large molecular weight limits blood-brain barrier penetration
New modality risks: Limited clinical experience in CNS
E3 ligase dependency: Limited to proteins amenable to ubiquitination by available ligases
Safety concerns: Off-target degradation and unexpected toxicities
Duration of effect: May require continuous dosing for sustained benefit

Future Directions

The therapeutic landscape for neurodegenerative diseases is evolving toward combination approaches that address multiple aspects of disease pathogenesis simultaneously. Just as combination therapy has transformed HIV/AIDS and cancer treatment, neurodegenerative disease therapy will likely require multi-target strategies[@gaugler2023].

Combination Approaches

Emerging strategies include:

Antibody + small molecule: Combining amyloid clearance with neuroprotective agents
ASO + antibody: Targeting protein production and clearance through complementary mechanisms
Gene therapy + cell therapy: Providing trophic support alongside cellular replacement
Targeted protein degradation + immunotherapy: Eliminating existing pathology while preventing new aggregation

Emerging Technologies

Several emerging technologies may transform the field:

Brain shuttle technologies: Engineering antibodies and proteins to cross the blood-brain barrier more efficiently
Vectorized antibodies: Delivering antibody genes directly to the CNS via AAV
RNA targeting beyond ASOs: siRNA, miRNA, and CRISPR-based approaches
Cellular rejuvenation: Senolytics and cellular reprogramming approaches

Precision Medicine

The future will likely see increased personalization:

Genetic stratification: Matching therapies to underlying genetic causes
Biomarker-guided selection: Using amyloid PET, tau PET, or fluid biomarkers to select patients
Digital biomarkers: Monitoring treatment response through wearable devices and digital assessments

Cross-Links

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyloid-Beta](/proteins/amyloid-beta)
[Tau Protein](/proteins/tau)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[LRRK2](/genes/lrrk2)
[GBA](/genes/gba)
[Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
[Lewy Body Dementia](/diseases/lewy-body-dementia)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Long, J. M., & Holtzman, D. M. (2019). Alzheimer disease: An update on pathobiology and treatment strategies (2019)](https://doi.org/10.1016/j.cell.2019.09.001)

[Unknown, Karch, C. M., & Goate, A. M. (2015). Alzheimer's disease risk genes and mechanisms of disease pathogenesis (2015)](https://doi.org/10.1016/j.biopsych.2014.05.006)

[Unknown, Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019). A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease (2019)](https://doi.org/10.1038/s41582-018-0116-5)

[van Dyck, C. H., et al., (2023). Lecanemab in early Alzheimer's disease (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Pagano, G., et al, (2022) (2022)](https://doi.org/10.1016/S1474-4422(21)

[Unknown, Hudry, E., & Cousin, O. (2022). Gene therapy for neurodegenerative diseases (2022)](https://doi.org/10.1038/s41572-022-00364-6)

[Mendell, J. R., et al., (2017). Gene therapy for spinal muscular atrophy: Safety and early outcomes (2017)](https://doi.org/10.1542/peds.2016-2927)

[Unknown, Rinaldi, C., & Wood, M. J. A. (2018). Antisense oligonucleotides: The next frontier for treatment of neurological disorders (2018)](https://doi.org/10.1038/nrneurol.2017.148)

[Miller, T., et al, (2023) (2023)](https://doi.org/10.1056/NEJMoa2304632)

Unknown, Ionis. (2023). IONIS-MAPTRx demonstrates dose-dependent reduction of tau protein in Phase 1/2 study (2023)

[Cummings, J., et al, (2023) (2023)](https://doi.org/10.1002/trc2.12385)

[Jennings, D., et al, (2023) (2023)](https://doi.org/10.1016/S1474-4422(23)

[Athauda, D., et al, (2017) (2017)](https://doi.org/10.1016/S0140-6736(17)

[Barker, R. A., et al., (2023). Human pluripotent stem cell-derived neurons for disease modeling and drug discovery: Progress and recommendations (2023)](https://doi.org/10.1038/s41583-023-00736-1)

[Unknown, Békés, M., Langley, D. R., & Crews, C. M. (2022). PROTAC targeted protein degraders: The past is prologue (2022)](https://doi.org/10.1038/s41573-021-00371-4)

[Unknown, Mullard, A. (2024). FDA approves first targeted protein degrader (2024)](https://doi.org/10.1038/d41573-024-00045-9)

[Gaugler, J., et al, (2023) (2023)](https://doi.org/10.3233/JAD-220123)

📖 View canonical wiki page →

Related Entities

therapeutics-therapeutic-modalities

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-therapeutic-modalities
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2f7f0450c180
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-therapeutic-modalities'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

565

Outgoing

709

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Therapeutic Modalities in Neurodegeneration

Therapeutic Modalities in Neurodegeneration

Overview

Therapeutic Modalities in Neurodegeneration

Overview

Pathway Diagram

Comparison of Therapeutic Modalities

Antibody Therapies

Mechanism of Action

Clinical Status

Key Companies

Advantages

Limitations

Gene Therapy

Mechanism of Action

Clinical Status

Key Companies

Advantages

Limitations

Antisense Oligonucleotides (ASOs)

Mechanism of Action

Clinical Status

Key Companies

Advantages

Limitations

Small Molecule Drugs

Mechanism of Action

Clinical Status

Key Companies

Advantages

Limitations

Cell Therapy

Mechanism of Action

Clinical Status

Key Companies

Advantages

Limitations

Targeted Protein Degradation

Mechanism of Action

Clinical Status

Key Companies

Advantages

Limitations

Future Directions

Combination Approaches

Emerging Technologies

Precision Medicine

Cross-Links

See Also

External Links

References

💬 Discussion